



## FDA's New Communications and Compliance Tool for Device Data Integrity Concerns

March 12, 2025

Reading Time : **1 min**

By: Nathan A. Brown, Maddy L. Bolger

The Food and Drug Administration (FDA) has updated its website to provide new information on data integrity concerns relating to medical devices.

The FDA has expressed data integrity concerns about testing labs in the past year and has issued warning letters to certain testing labs for violations of good laboratory practices (GLPs). This new website page, “Notifications on Data Integrity—Medical Devices,” and the publication of a “General Correspondence Letter,” may signal a new tool for communicating compliance concerns about testing labs to the regulated industry.

For further analysis, please read our client alert [here](#), which covers the FDA's update in greater detail.

### Categories

Policy & Regulation

Health Care

Health Information Privacy & Security

Regulatory

Food and Drug Administration (FDA)

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.